Abstract: Conjugated linoleic acid (CLA) consists of a group of naturally occurring and synthetic positional and geometric (cis-trans) stereoisomers of the polyunsaturated fatty acid linoleic acid. The cis-9,trans-11 (c9,t11) CLA isomer (the most prevalent form found in ruminant-derived foods) and the trans-10,cis-12 (t10,c12) CLA isomer (present in commercial preparations) are the two most widely studied CLA isomers in breast cancer. Studies using both animal and cell culture models indicate that these CLA isomers, when added to the diet or included in the cell culture medium, inhibit mammary tumour initiation, promotion and progression in rodents, and alter tumour cell viability in vitro. The mechanism of CLA's anticancer effect is not well understood, but may involve interference with the cell cycle, induction of apoptosis, modulation of gene expression via the activation of peroxisome proliferator-activated receptors, lipid peroxidation, modulation of the tumour microenvironment, changes to the structure and/or function of the cell membrane, and interference with growth factor receptor signaling. A greater understanding of the mechanism of action of CLA will support the development of clinical trials to evaluate the potential effectiveness of CLA in the treatment of breast cancer.
INTRODUCTION
The pioneering work of Dr. T.K. Basu at the University of Alberta, Edmonton, Canada has demonstrated that both classical nutrients such Vitamin B-6 [1] , niacin [2] and fiber [3] and isolated phytochemicals such as echinacea [4] and fenugreek [5] can have health benefits in the treatment and prevention of chronic and acute diseases. In 1981, Doll et al. estimated that 30% of all cancers could be prevented by dietary factors [6] . Epidemiological and animal studies support the hypothesis that nutritional factors play an important role in the etiology of breast cancer [7, 8] . There is a growing interest in the potential role of neutraceuticals as these 'nutritional factors' that might have efficacy in both the prevention and treatment of cancer. In 1979, Pariza et al. discovered an anti-carcinogenic property of fried ground beef [9] . By 1987, the compound was isolated and identified as a polyunsaturated fatty acid (PUFA) called conjugated linoleic acid (CLA) [10] . Since then, numerous animal and cell culture studies have demonstrated that CLA may protect against breast cancer. The remainder of this review will describe what is currently known about the anti-carcinogenic properties of CLA in breast cancer and potential mechanisms for its anti-cancer properties.
Conjugated Linoleic Acid (CLA)
CLA consists of a group of positional and geometric (cis-trans) stereoisomers of linoleic acid (LA) that are *Address correspondence to this author at the Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-126A HRIF East, Edmonton, Alberta, Canada T6G 2E1; Tel: (780) 492-2597; Fax: (780) 492-2011; E-mail: Catherine.Field@ualberta.ca commercially synthesized from plant oils [11] or formed during the biohydrogenation of LA to stearic acid by ruminant animals [12] . The cis-9,trans-11 (c9,t11) CLA isomer is the most prevalent form found in ruminant-derived foods (e.g. milk and meat) [12] . The trans-10,cis-12 (t10,c12) CLA isomer is present only in trace amounts in animal foods but is found in an approximate 50:50 ratio with c9,t11 CLA in commercial CLA preparations [12] .
There are varying estimates in the literature as to the current average intake of CLA by the general population in westernized countries, ranging from 95 to 430 mg per day [13] [14] [15] [16] . These estimates are complicated by the variability of CLA content in food sources due to differences in feeding practices and inter-animal differences which affect the production of CLA in the rumen and mammary gland [17] . This variability in the food supply has made it challenging to study the intake of CLA in the general population and its effect on health.
Human Studies Of CLA and Breast Cancer
To date there have been no clinical trials in humans to test the effects of CLA on breast cancer prevention or treatment. The only human data available is from epidemiological studies. Five such studies have examined the relationship between CLA intake and risk of breast cancer ( Table 1 ). The results of these studies are conflicting: both an increased and decreased risk of breast cancer have been reported for CLA consumption. The epidemiological studies may be limited by the variability of CLA in the food supply as well as the difficulty of assessing the intake of this minor dietary component.
Animal Studies of CLA and Mammary Cancer
Numerous studies using various animal models support the hypothesis that both synthetic and naturally enriched sources of CLA added to the diet inhibit mammary tumour initiation [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , promotion and progression [35] [36] [37] [38] [39] [40] [41] in rodents ( Table 2) . A range of 0.1% to 1% w/w of CLA, independent of the level and type of fat in the diet, has shown to be effective, with no further benefits beyond 1% w/w [19, 24] . The stage at which CLA is introduced in the diet appears to impact its effectiveness. When Ip et al. [20] provided CLA solely during mammary development prior to the injection of carcinogen, the protection against mammary cancer continued for the duration of the study even though CLA was no longer in the diet. In contrast, if CLA was introduced in the diet after mammary development, its intake had to be continuous for the remainder of the experiment to confer a protective effect [20] . In contrast to the majority of animal studies, no effect on tumour growth was observed with the injection of WAZ-2T mammary cancer cells into a mouse model. Furthermore, the t10,c12 CLA isomer was shown to increase initiation rate and lung metastasis, although not survival time, in a transgenic mouse overexpressing the growth receptor ErbB2 [42, 43] . CLA has been shown to dramatically alter fat deposition and body weight in mice [44] . Thus, the transgenic mouse model effects may have been due to changes to the stroma (which consists partly of adipocytes) surrounding the cells rather than the epithelial cells themselves [43] .
Cell Culture Studies of CLA and Breast Cancer
Consistent with the in vivo results, CLA provided as individual isomers, a 50:50 mixture of c9,t11 CLA and t10,c12 CLA, or as CLA-enhanced milk fat decreases the growth, viability and/or increases death in a variety of breast cancer cell lines as reviewed in Table 3 . Effectiveness has ranged from 10-200 µM, which falls within the concentrations of CLA that have been observed in human serum (10-350 µM), including among people taking CLA supplements long-term [45] .
Some studies have provided CLA as a free fatty acid in ethanol, whereas others conjugated CLA to the carrier protein albumin. Free fatty acids are toxic to cells and desBordes and Lea [46] showed that by increasing the albumin to fatty acid ratio there was a decrease in the inhibitory effect of CLA. This difference in supply of fatty acids may explain why some studies were able to see inhibition at lower concentrations of CLA than others.
POTENTIAL MECHANISMS OF CYTOTOXICITY OF CLA ISOMERS TO BREAST CANCER CELLS
Interference with the Cell Cycle CLA treatment of breast cancer cell lines has been reported to interfere with progression of the cell cycle. Studies in human breast cancer cell lines have shown an accumulation of cells in the G0/G1 (resting/growth) phase along with a corresponding decrease in the mRNA or protein expression of cell cycle promoters (e.g. c-myc, cyclin D1) and increased mRNA or protein expression of negative cell cycle regulators (p53, p21 Cip1/WAF1 , p27) with CLA treatment [47] [48] [49] [50] [51] . The t10,c12 CLA isomer was more effective at inhibiting proliferation than c9,t11 CLA in the MCF-7 breast cancer cell line [48] .
Induction of Apoptosis
CLA treatment is reported to increase apoptosis in human and rodent mammary cancer cells [25, [51] [52] [53] [54] [55] [56] . Some of the observed changes consistent with the induction of apoptosis include: increased wild-type p53 protein levels, chromatin condensation, increased pro-apoptotic bax and bak protein levels, reduced anti-apoptotic bcl-2 protein levels, increased cytochrome c in the cytosol, and increased cleavage of initiator and effector caspases, reduced COX-2 activity and the generation of PGE 2 [25, 51, 52, [54] [55] [56] [57] . A recent report indicated that t10,c12 CLA induces apoptosis in TM4t mammary tumour cells using certain components of the endoplasmic reticulum (ER) stress response, an alternative pathway to apoptosis in addition to the classical death receptor ("extrinsic") or mitochondrial ("intrinsic") pathways [53] . The mechanism of CLA-induced ER stress was proposed to involve increased lipid peroxidation products among CLAtreated cells [53] .
Activation of Peroxisome Proliferator-Activated Receptors
Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that have been implicated in multiple cell processes including regulation of the cell cycle Abbreviations: AA, arachidonic acid; BSA, bovine serum albumin; COX, cyclooxygenase; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor; ER, estrogen receptor; ERE, estrogen response element; ERK, extracellular signal-regulated kinase; FA, fatty acids; FBS, fetal bovine serum; 5-HETE, 5-hydroxyeicosatetraenoic acid; HMEC, human mammary epithelial cells; IGF-IR, insulin-like growth factor I receptor; LA, linoleic acid; MTT, methylthiazolyldiphenyl-tetrazolium bromide; NDGA, nordihydroguaiaretic acid; OA, oleic acid; PGE2, prostaglandin E2;PGF2 α , prostaglandin F 2α; PKC, protein kinase C; PL, phospholipids; PLC, phospholipase C; PPAR, peroxisome proliferator activated receptor; ppm, parts per million; VA, vaccenic acid.
and apoptosis. They consist of three isoforms (PPARα, PPARβ/δ and PPARγ) that are distributed in various tissues of the body and appear to have different yet also overlapping roles [58] . PPARs regulate gene expression by forming a heterodimer with retinoid x receptors, then binding to specific response elements in the promoter regions of target genes. PPARγ appears to be highly involved in adipocyte regulation, but it also appears as though its agonists target multiple hallmarks of cancer, including cell cycle arrest, differentiation, apoptosis, and angiogenesis [58] . PPARγ is expressed in human breast adenocarcinomas [59] and its upregulation decreases the proliferation of MCF-7 cells [60] . The role of PPARβ/δ ligands in tumourigenesis continues to be debated in the research literature [61] ; there is evidence to support that they stimulate the growth of breast cancer cell lines [62] . There is limited data on the role of PPARα agonists in cancer, however a PPARα ligand has been shown to induce apoptosis in human breast cancer cell lines [63] .
PUFAs and their metabolites are ligands for PPARs [64] [65] [66] . CLA treatment of MCF-7 breast cancer cells was shown to increase protein levels of the anti-proliferative PPARγ and decrease protein levels of the anti-apoptotic PPARβ/δ [67, 68] . CLA also increased the localization of PPARγ from the cytosol to the nucleus, and increased PPAR response element activation [68, 69] . Use of a PPARγ antagonist abolished the growth inhibitory effects of CLA [68] . CLA exerted different effects on the estrogen receptor-negative MDA-MB-231 cell line [67] . It increased protein levels of the PPARγ2 isoform, yet it also increased PPARβ/δ levels, which may explain why CLA did not induce apoptosis in the MDA-MB-231 cells. Of note, none of these studies compared the effect of CLA on PPARs to that of other known PPAR agonists, such as linoleic, oleic or linolenic acids.
Effects on the Tumour Microenvironment
The tumour microenvironment plays an active role in tumourigenesis. The tissue that surrounds and intercalates between cancer cells is termed the tumour stroma and it consists of the extracellular matrix (ECM), immune and inflammatory cells, fibroblasts, adipocytes, and endothelial cells. Cross-talk between cancer and stromal cells is important for the creation of a microenvironment supportive of malignant tumour growth as well as for the promotion and progression of the tumour [70] . Cancer cells release growth factors such as basic fibroblast growth factor and the family of vascular endothelial growth factors (VEGF) to stimulate changes in the stroma to support the tumour's development. Proteases are also released, which remodel the surrounding ECM to allow the spreading of the cancer cells. Once activated, stromal fibroblasts produce more growth factors to stimulate the continued growth of the cancer cells [70] . The formation of blood vessels (angiogenesis) is critical to support tumour growth and progression. Cross talk between cancer cells that release VEGF and stromal endothelial cells that express the VEGF2 receptor results in local angiogenesis. Blocking VEGF2 has been shown to reverse invasive carcinoma to a pre-malignant non-invasive tumour phenotype [70] .
Including CLA (up to 1% w/w) in the diet has been shown to alter mammary gland development during puberty in rodents [24] . CLA decreased epithelial branching and the density of terminal end buds, which are highly susceptible to carcinogenesis [24, 71] . The epithelial branching and terminal end bud formation of mammary gland development are dependent on the presence of stromal fibroblasts [72] , which suggests CLA may interfere with signaling between the stroma and epithelial cells. There is evidence to support that the decreased epithelial branching could be due to CLA's direct inhibition of epithelial growth; however, changes in adipocyte stroma due to incubation with CLA have been observed and could also contribute [25, 71] .
Both c9,t11 CLA and t10,c12 CLA have been shown to decrease the formation of microcapillary networks in mice and in vitro, although t10,c12 was more potent [37, 39] . Changes to pathways related to angiogenesis included: decreased VEGF-A serum levels, decreased local production of VEGF in the mammary gland, decreased VEGF2 receptor protein, and decreased serum leptin (which promotes angiogenesis through endothelial cells) [37, 39, 45] . Studying the effect of CLA on the stroma in the mouse model has been hampered by t10,c12 CLA's complete ablation of brown adipose tissue in the mammary gland, which thereby would change the composition of the surrounding stroma. However, in other tissues, the ability of CLA to reduce angiogenesis is well characterized [73] . Recent studies also report a reduction in the activity of matrix metalloproteinases in both mammary tumours [74] and colon cancer cells [75] with CLA treatment, suggesting an additional mechanism by which CLA may reduce tumour invasion and spread.
Lipid Oxidation
Tumour cells demonstrate an increased susceptibility to oxidative stress, and current chemotherapy and radiation treatments derive their cytotoxic effects from increasing oxidative stress [50] . Due to their double bond structure, PUFAs and their metabolic products have an increased susceptibility to oxidation. Lipid peroxidation products have been shown to cause cell cycle arrest and induce tumour cell death [76] . There is conflicting research suggesting that CLA either augments or reduces oxidative stress in breast cancer cells. Albright et al. reported a preferential increase in oxidative stress and a resulting inhibition of the cell cycle with 50 µM of a CLA mixture in MCF-7 cells as compared to normal mammary epithelial ductal cells (MCF-10A) [50] . CLA treatment has also been shown to increase the activity of superoxide dismutase, catalase and glutathione peroxidase (protective enzymes against oxidative stress) [77] , as well as increase the lipid peroxidation product 8-epi-PG (prostaglandin)F2α [78] . These findings support the argument that CLA induces oxidative stress. In contrast, a one month CLA feeding trial in Sprague-Dawley rats showed that a CLA mixture reduced the presence of lipid peroxidation products in the mammary gland [18] . Research into other models of cancer also report conflicting results regarding CLA's potential role in oxidative stress [10, 79] . Some believe that CLA's interference with the metabolism of other fatty acids, such as linoleic acid (LA, which may be more susceptible to peroxidation) is the pathway by which it has an effect on oxidation [24] .
Changes to Cell Membrane Structure and Function
PUFAs with cis-double bonds are believed to impact the physical properties of the cell membrane due to their 'kinked' structure, which allows for less tight packing of surrounding fatty acyl groups [80] . In contrast, the incorporation of the straighter trans fatty acids into membranes has been shown to decrease membrane fluidity and interfere with the function of membrane receptors [81] [82] [83] . Changes to the dietary fatty acid composition of the plasma membrane and subsequently the physical structure have been shown to alter lipid-protein interactions, affect ion transporters, receptors, signal transducers and enzymes [80, [84] [85] [86] . The two most commonly investigated CLA isomers, c9,t11 and t10,c12, contain both a cis and a trans bond. When provided in the diet or cell culture medium, CLA isomers are readily incorporated into the phospholipids of tumour cell membranes [87, 88] . The trans-bond in the major CLA isomers has the potential to alter the physical structure of the membrane and this could then alter the function of important proteins and signals that are located or generated from the plasma membrane. Recently it was demonstrated that incubation with CLA was associated with a reduction in the expression of the membrane receptor HER2 in the HER-2 expressing breast cancer cell line SKBr3 [55] and incorporation of both of the major isomers of CLA in the membrane phospholipids was associated with a reduction in the amount of the IGF-1 receptor in MCF-7 cells [88] .
The impact of CLA incorporation into membranes on essential fatty acid metabolism and the subsequent production of eicosanoids has been studied. Due to the chemical similarities between LA and CLA, it was initially hypothesized that CLA may compete with the incorporation or metabolism of LA in membrane phospholipids and thereby interfere with the synthesis of the essential fatty acid arachidonic acid (AA, C20:4n-6) [89] . AA is a substrate for eicosanoids: prostaglandins are produced from AA via cycloxygenase enzymes and leukotrienes are produced via lipoxygenase enzymes. Eicosanoids are hormone-like compounds that exert many cellular functions and have been demonstrated to be involved in cell growth and apoptosis in human breast cancer [90] . Neither major isomer of CLA, nor a CLA mixture, appears to decrease the incorporation of LA in membrane phospholipids [21, 24, 91, 92] . However, CLA has been reported to interfere with essential fatty acid metabolism. Both a CLA mixture (c9,t11 and t10,c12) and/or t10,c12 CLA alone reduce the elongation and desaturation products of LA, most importantly AA [24, 92] . Consistent with this, CLA has been reported to interfere with the production of PGE 2 as well as 5-HETE, an important substrate of the lipoxygenase pathway [55, 87, 93] . The distribution of fatty acids among the different phospholipid classes of the plasma membrane influences eicosanoid production. Phospholipase A2 preferentially detaches fatty acids from phosphatidylcholine (PC), making PC the preferential source of AA for eicosanoid synthesis. Miller et al. [94] showed that CLA decreases the amount of AA stored in PC and increases it in phosphatidylethanolamine (PE) along with a subsequent decrease in the production of PGE 2. Although these researchers have reported that CLA may interfere with essential fatty acid metabolism, the more effective isomer is still controversial [92, 94] .
Interestingly, a recent study reported that either a mixture of CLA isomers or t10,c12 CLA was effective at reducing the transcriptional activity of the cyclooxygenase-2 (COX-2) promoter in MCF-7 cells (the c9,t11 CLA isomer was less effective), suggesting an alternative mechanism by which CLA may interfere with eicosanoid metabolism [95] . Additionally, a recent study suggests that a mixture of CLA isomers decreased S14 and fatty acid synthetase in T47D breast cancer cells [96] , suggesting that CLA also interferes with fatty acid synthesis in these cancer cells.
Interference with Growth Factor Receptors/Signaling Pathways
The insulin-like growth factor (IGF) and epidermal growth factor (EGF) are proteins that stimulate cell proliferation and inhibit apoptosis. Their receptors and/or signaling pathways are often up-regulated in cancer [97] . Some current chemotherapy treatments are designed, or are in the process of being designed, to interfere with growth factor promotion of cell growth. For example, Trastuzumab (Herceptin), blocks the function of the Her2/neu/ErbB2 receptor (part of the EGF family), which is often overexpressed in breast cancers [97] . Recently, it was demonstrated that incubation with t10,c12 CLA reduced HER2 expression in SKBr3 cells [55] .
At this time, little is known about the effects of CLA on EGF signaling. Recently we demonstrated that incubation with either major isomer of CLA decreased the cellular concentrations of IGF-1 in MCF-7 cells [88] . Only a small number of studies have investigated the effects of CLA on IGF-I signaling. In vitro, CLA interferes with IGF signaling in the HT-29 human colon cancer cell line [98] . IGF-1 is essential for pubertal mammary development of the terminal end buds [72, 99] . Studies using rodent mammary cancer models have shown that CLA interferes with terminal end bud development [100] , providing preliminary support for an inhibitory effect of CLA on IGF signaling. Since then, CLA has been reported to interfere with insulin-stimulated proliferation of MCF-7 cells in vitro, with t10,c12 CLA showing greater inhibition than c9,t11 CLA or a CLA mixture [101] . Studies from our own laboratory showed that t10,c12 CLA (but not c9,t11 CLA) reduced the levels of phosphorylated IGF-1 receptor in MCF-7 cells [88] . In contrast to the cell culture studies, Meng et al. recently reported the results of an animal feeding study in which t10,c12 CLA, when fed to female transgenic mice bearing ErbB2-overexpressing mammary tumours, increased mammary tumour growth and increased phosphorylation of the IGF-IR/IR and its downstream targets PI3K, Akt, MEK, and ERK [102] . The CLA-induced stimulation of tumour growth in this model is consistent with a previous report by this group [43] . It is not clear whether the conflicting reports between in vitro and in vivo studies are related to differences in tumour model or to the contribution of the tumour microenvironment in vivo, but clearly further research is warranted.
SUMMARY
The interest and evidence that CLA may become a future neutraceutical treatment for the treatment and prevention of cancer is rapidly growing. The evidence is summarized in Tables 1-3 . Basic research into the mechanisms behind the anti-carcinogenic effect of CLA offers insight into its modifications to cellular function and the surrounding stromal environment. From a review of the current literature, it can be concluded that CLA has the potential to target multiple characteristics or hallmarks of cancer such as apoptosis, angiogenesis and sensitivity to growth signals. The convincing anticancer effects of both major CLA isomers that have been observed in human tumour cell lines and animal models of cancer provide preliminary evidence to suggest an application in humans. Dr. T.K. Basu so elegantly demonstrated during his career that one needs to demonstrate an effect first in vitro/in situ [103, 104] , then in the appropriate animal models [3] [4] [5] and finally demonstrate efficacy in well designed human trials [105] [106] [107] . Thus, before trials can be proposed to test efficacy of CLA, it is necessary to elucidate the biological mechanism(s) that might explain the antitumour effects of the CLA isomers. This possible mechanism would need to be novel and/or complementary to current therapies available for the treatment of breast cancer. More animal studies are required before the progression to human clinical trials to further establish the specificity of CLA to mammary cancer and effectiveness of a plausible intake of CLA for human trials. A greater understanding of CLA's mechanism of action will support the development of clinical trials to evaluate the potential effectiveness of CLA in the treatment of breast cancer.
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